St. Jude cardiac resynchronization therapy approved in Europe

By Elaine Rigoli

Tampa, Fla., June 16 - St. Jude Medical, Inc. has received European CE Mark approval and European market launch of its QuickOpt timing cycle optimization.

The company also released trial results that found that QuickOpt optimization consistently was comparable to a traditional echocardiography (echo) procedure for determining optimal conduction delays.

QuickOpt procedures in the study were completed within two minutes, while echo optimization typically takes between 30 and 120 minutes and requires a manual investigation by a technician, the company said in a news release.

Results showed QuickOpt optimization correlated consistently with echo more than 96% of the time for both atrial-ventricular timing and for ventricular-ventricular timing.

The study endpoint required a correlation greater than 90%, the release said.

Based in St. Paul, Minn., St. Jude Medical is dedicated to making life better for cardiac, neurological and chronic pain patients.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.